Calidi Biotherapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
CLDI$0.73+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Total Equity
CONDENSED CONSOLIDATED STATEMENTS OF TOTAL EQUITY
(Unaudited)
(In thousands, except share amounts)
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | |||||||
| Balance at December 31, 2025 | 7,216,994 | $1 | $145,392 | $(13) | $(141,621) | - | $3,759 |
| Issuance of common stock through March Confidentially Marketed Public Offering, net of financing costs | 2,278,731 | — | 5,057 | — | — | 5,057 | |
| Exercise of pre-funded warrants | 2,291,000 | — | 5 | — | — | 5 | |
| Stock-based compensation | — | — | 231 | — | — | 231 | |
| Foreign currency translation adjustments | — | — | — | (9) | — | (9) | |
| Net loss | — | — | — | — | (4,108) | - | (4,108) |
| Balance at March 31, 2026 | 11,786,725 | $1 | $150,685 | $(22) | $(145,729) | - | $4,935 |
| Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ · Non controlling · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | Interest | Equity | |
| Balance at December 31, 2024 | 1,730,051 | $— | $123,277 | $(28) | $(121,715) | $1,534 | $434 | $1,968 |
| Issuance of common stock through At the Market Offering | 223,583 | — | 2,754 | — | — | 2,754 | — | 2,754 |
| Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs | 416,667 | — | 3,607 | — | — | 3,607 | — | 3,607 |
| Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs | 277,084 | — | 3,423 | — | — | 3,423 | — | 3,423 |
| Restricted stock unit shares released | 2,038 | — | — | — | — | — | — | — |
| Stock-based compensation | — | — | 607 | — | — | 607 | — | 607 |
| Foreign currency translation adjustments | — | — | — | 2 | — | 2 | — | 2 |
| Net loss | — | — | — | — | (4,986) | (4,986) | (76) | (5,062) |
| Balance at March 31, 2025 | 2,649,423 | $— | $133,668 | $(26) | $(126,701) | $6,941 | $358 | $7,299 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.